西地尼布抗肿瘤作用的临床研究进展.pdf

西地尼布抗肿瘤作用的临床研究进展  金燕芬 1 2 ，沈威 (1.杭州华东医药集团新药研究院有限公司，杭州 310011 ；2.杭州中美华东制药有限公司，杭州 310011) 摘要：目的 介绍西地尼布的多种抗肿瘤作用临床研究进展。方法 检索近年来国内外相关的文献报道，对西地尼布用 于卵巢癌、实体瘤、胆道癌、肾细胞癌、前列腺癌、宫颈癌和结肠癌这七大领域的临床试验进行综述。结果 西地尼布 是一种强效的血管内皮生长因子受体抑制剂，大量临床试验资料表明它有潜力用于各种肿瘤。药动学研究显示它口服给 药，每日 1 次，用药方便，且毒性反应与其他血管内皮生长因子受体抑制剂相似。结论 熟悉西地尼布的临床应用，对 更好的开发西地尼布具有深远意义。 关键词：西地尼布；AZD2171 ；血管内皮生长因子受体抑制剂；卵巢癌 中图分类号：R969.3 文献标志码：A 文章编号：1007-7693(2017)01-0143-04 DOI: 10.13748/ki.issn1007-7693.2017.01.033 Clinical Advances of Anti-tumor Effects of Cediranib 1 2 JIN Yanfen , SHEN Wei (1.Hangzhou Huadong Medicine Group Pharmaceutical Research Institute Co., Ltd., Hangzhou 310011, China; 2.Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd., Hangzhou 310011, China) ABSTRACT: OBJECTIVE To introduce kinds of cediranib’s antitumor effects in clinic. METHODS According to the correlative reports in recent years, clinical trial of the seven areas of ovarian cancer, solid tumors, biliary tract cancer, renal cell carcinoma, prostate cancer, cervical cancer and colon cancer were reviewed. RESULTS Cediranib was a potent inhibitor of VEGFR, datas from clinical studies of cediranib suggested its potential anti-tumor effect. Pharmacokinetic studies showed that it was oral administration, once daily, conveniently, and it’s toxicity was similar to other VEGFR inhibitors. CONCLUSION Familiar with the clinical application of cediranib, has profound significance for the development of better cediranib. KEY WORDS: cediranib; AZD2171; VEGFR inhibitors; ovarian cancer 西地尼布(AZD2171)是一种口服抗肿瘤药物， 本文就西地尼布在国外已进行的卵巢癌、实 由美国阿斯利康公司研发，化学名为 4-(4-氟-2- 甲 体瘤、胆道癌、肾细胞癌、前列腺癌、宫颈癌和 基吲哚-5-基氧基)-6- 甲氧基-7-[3-(吡